Evidence map›Paper›PMID 36993972›Full record

ReviewFrontiers in immunology2023

Role of the inflammasome in insulin resistance and type 2 diabetes mellitus.

Shen Lu, Yanrong Li, Zhaojun Qian, Tiesuo Zhao, Zhiwei Feng, Xiaogang Weng, Lili Yu

Open access · goldFull text readReview
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Insulin Resistance and Inflammation.International journal of molecular sciences · 2026
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. CD4Frontiers in immunology · 2026
    Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shen LuThe Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Yanrong LiSchool of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan, China.
Zhaojun QianThe Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Tiesuo ZhaoSchool of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan, China.
Zhiwei FengSchool of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan, China.
Xiaogang WengThe Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Lili YuThe Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Xinxiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inflammasome is a protein complex composed of a variety of proteins in cells and which participates in the innate immune response of the body. It can be activated by upstream signal regulation and plays an important role in pyroptosis, apoptosis, inflammation, tumor regulation, etc. In recent years, the number of metabolic syndrome patients with insulin resistance (IR) has increased year by year, and the inflammasome is closely related to the occurrence and development of metabolic diseases. The inflammasome can directly or indirectly affect conduction of the insulin signaling pathway, involvement the occurrence of IR and type 2 diabetes mellitus (T2DM). Moreover, various therapeutic agents also work through the inflammasome to treat with diabetes. This review focuses on the role of inflammasome on IR and T2DM, pointing out the association and utility value. Briefly, we have discussed the main inflammasomes, including NLRP1, NLRP3, NLRC4, NLRP6 and AIM2, as well as their structure, activation and regulation in IR were described in detail. Finally, we discussed the current therapeutic options-associated with inflammasome for the treatment of T2DM. Specially, the NLRP3-related therapeutic agents and options are widely developed. In summary, this article reviews the role of and research progress on the inflammasome in IR and T2DM.

Indexed as

Diabetes Mellitus, Type 2Insulin ResistanceHumansImmunity, InnateInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesNLR Family, Pyrin Domain-Containing 3 Proteininflammasomeinsulin resistanceNLRP3therapeutic agentstype 2 diabetes mellitus

Identifiers

PMID36993972
PMCPMC10040598
OpenAlexW4324082555

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read20
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.